QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RCUS

QT59Arcus Biosciences, Inc.
NYSE·Healthcare·Biotechnology·USA
Latest market price
24.31
+0.19+0.79%
OverviewShort InterestFilings
RCUSQT59Arcus Biosciences, Inc.·NYSE
OverviewShort InterestFilings
24.31+0.79%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.17
Insider Own49.52%
Shs Outstand125.77M
Perf Week4.33%
Market Cap2.43BForward P/E-EPS next Y-3.44Insider Trans0.02%Shs Float-Perf Month6.86%
Enterprise Value2.34BPEG-EPS next Q-0.89Inst Own-Short Float-Perf Quarter8.38%
Income-296238923.00P/S10.29EPS this Y-16.04%Inst Trans-Short Ratio-Perf Half Y9.50%
Sales236.00MP/B5.77EPS next Y6.39%ROA-37.01%Short Interest-Perf YTD2.01%
Book/sh4.17P/C-EPS next 5Y-ROE-68.97%52W High28.72 -15.36%Perf Year179.43%
Cash/sh6.54P/FCF-EPS past 3/5Y-ROIC-49.69%52W Low7.91 207.33%Perf 3Y-
Dividend Est.-EV/EBITDA-7.09Sales past 3/5Y30.16% 25.93%Gross Margin97.03%Volatility3.17% 3.96%Perf 5Y-
Dividend TTM-EV/Sales9.92EPS Y/Y TTM-3.67%Oper. Margin-168.64%ATR (14)1.36Perf 10Y-
Dividend Ex-Date-Quick Ratio4.04Sales Y/Y TTM-8.53%Profit Margin-156.36%RSI (14)52.06Recom2.40
Dividend Gr. 3/5Y-Current Ratio4.04EPS Q/Q10.53%SMA201.41%Beta1.97Target Price31.00
Payout0.00%Debt/Eq0.22Sales Q/Q-39.29%SMA500.19%Rel Volume1.98Prev Close24.12
Employees627LT Debt/Eq0.16EarningsAug 05SMA20016.02%Avg Volume1.17MPrice24.31
IPO DateMar 15, 2018Option/ShortYes / YesEPS/Sales Surpr.-10.87% -41.38%Net Debt/EBITDA0.27Volume2,308,995Change0.79%
Analyst Ratings
DateActionAnalystRatingTarget
May-18-26ReiteratedTruist Financial$30 → $35
May-11-26ReiteratedMorgan StanleyEqual Weight$20 → $22
Apr-20-26ReiteratedLeerink PartnersOutperform$49 → $47
Feb-12-26DowngradeWells FargoOverweight → Equal Weight$26 → $23
Jan-13-26UpgradeGoldman SachsNeutral → Buy$28
Jan-08-26DowngradeMorgan StanleyOverweight → Equal Weight$35 → $20
Dec-12-25ReiteratedTruist Financial$39 → $30
Dec-12-25ReiteratedH.C. Wainwright$28 → $32
Oct-30-25ReiteratedGoldman SachsNeutral$16
Oct-29-25ReiteratedWedbushOutperform$33 → $35
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue236247258
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A7100
Gross Profit229237258
Selling, General and Administrative Excl. Other111110120
Research and Development523523448
Other Operating Expense-7-1020
Operating Income-398-386-330
Interest Expense2284
Unusual Expense
———
Non-Operating Income (Expense)-59-41-51
Net Income Before Taxes-369-353-283
Income Taxes001
Consolidated Net Income-369-353-283
Net Income From Continuing Operations-369-353-284
Net Income-369-353-283
EPS (Recurring)-3.17-3.29-3.14
EPS (Basic, Before Extraordinaries)-3.17-3.29-3.14
EPS (Diluted)-3.17-3.29-3.14
EBITDA-330-335-269
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio12.8810.32—
Gross Margin97.0395.95100.00
Operating Margin-168.64-156.28-127.91
Net Margin-156.36-142.91-109.69
Shares Outstanding12510790
Market Capitalization3,0392,550—
Operating Lease Expense
———
Insider Trading Volume
$25.88$22.48$19.09$15.70$12.30● Close Price0.00M1.34M2.67M4.01M5.34MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Tang Carolyn C.General CounselJun 11 '26Option Exercise2.5768,180175,496184,607Jun 12 12:00 AM
Azoy AlexanderChief Accounting OfficerJun 01 '26Sale25.772,56266,02439,581Jun 01 12:00 AM
Goeltz II Robert C.Chief Financial OfficerMay 11 '26Sale25.637,763198,96684,161May 12 12:00 AM
Jaen Juan C.PresidentJan 05 '26Sale21.4131,823681,342922,240Jan 07 12:00 AM
Goeltz II Robert C.Chief Financial OfficerDec 31 '25Sale23.386,552153,18667,924Jan 02 12:00 AM
Azoy AlexanderChief Accounting OfficerDec 18 '25Sale22.254,34396,61418,531Dec 18 12:00 AM
Goeltz II Robert C.Chief Financial OfficerDec 17 '25Sale22.165,960132,07174,476Dec 18 12:00 AM
Tang Carolyn C.General CounselDec 17 '25Sale22.166,810150,906124,734Dec 18 12:00 AM
Jaen Juan C.PresidentDec 17 '25Sale22.169,983221,218346,012Dec 18 12:00 AM
Markus RichardChief Medical OfficerDec 17 '25Sale22.164,49499,58565,647Dec 18 12:00 AM
ROSEN TERRY JChief Executive OfficerDec 17 '25Sale22.1625,744570,4742,194,809Dec 18 12:00 AM
Azoy AlexanderChief Accounting OfficerDec 17 '25Sale22.162,11346,82322,874Dec 18 12:00 AM
Jarrett JenniferChief Operating OfficerDec 17 '25Sale22.169,983221,218193,024Dec 18 12:00 AM
Azoy AlexanderChief Accounting OfficerDec 16 '25Sale21.882,37651,99724,987Dec 18 12:00 AM
Tang Carolyn C.General CounselDec 16 '25Sale21.887,658167,590131,544Dec 18 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR